Relapsed or Refractory Follicular Lymphoma (r/rFL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Follicular lymphoma (FL), often called indolent lymphoma, is the second most prevalent type of non-Hodgkin lymphoma (NHL). Despite treatment, a considerable number of FL patients experience treatment failure, leading to classification as refractory lymphomas. Others initially respond positively but subsequently display signs of recurrent tumor growth, termed relapsed follicular lymphoma. The advanced-stage disease is typically deemed incurable, marked by a protracted pattern of relapse and remission. A notable subset of patients, particularly those with transformed or rapidly progressive disease, face less favorable outcomes. Bone marrow biopsy is typically reserved for individuals presenting with unexplained cytopenias. FL has the potential to progress into a more aggressive form of lymphoma, such as diffuse large B-cell lymphoma. Thus, biopsy remains crucial for diagnosing this transformation upon relapse. The advent of anti-CD20 monoclonal antibodies (mAbs) like rituximab and, more recently, type II anti-CD20 mAbs such as obinutuzumab, has revolutionized FL management, with anti-CD20 antibodies expected to retain prominence in FL treatment strategies. The intricate interplay between FL tumor cells and their distinct immune microenvironment has spurred the development of novel targeted therapies leveraging the immune system's capacity to combat malignant cells.

·       Follicular lymphoma (FL) ranks as the second most prevalent form of lymphoma in the United States, accounting for approximately 15,000 cases annually. Approximately 20% of FL patients experience a more aggressive disease trajectory characterized by frequent relapses, shorter periods of remission, and diminished overall survival rates.

 

Thelansis’s “Relapsed or Refractory Follicular Lymphoma (r/rFL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Follicular Lymphoma (r/rFL) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Relapsed or Refractory Follicular Lymphoma (r/rFL) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Follicular Lymphoma (r/rFL) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Relapsed or Refractory Follicular Lymphoma (r/rFL) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Relapsed or Refractory Follicular Lymphoma (r/rFL), Relapsed or Refractory Follicular Lymphoma (r/rFL) market outlook, Relapsed or Refractory Follicular Lymphoma (r/rFL) competitive landscape, Relapsed or Refractory Follicular Lymphoma (r/rFL) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more